Extended release pharmaceutical compositions comprising mycophenolate sodiumas the active agent, wherein the said composition exhibits a characteristicrelease profile when subjected to in-vitro dissolution study, and wherein saidmycophenolate sodium is released in a sustained manner in-vivo for a prolongedduration in such quantities that substantially alleviates or at least reducesthe chances of causing any associated gastrointestinal side effect(s) withoutcompromising the bioavailability of the said active agent are provided. Thepresent invention also provides process of preparing such dosage form compositionsand prophylactic and/or therapeutic methods of using such dosage form. The compositionof the present indention are safe, effective and well-tolerated, and are usefulfor the management such as prophylaxis, amelioration and/or treatment of immunosuppressantindicated disease(s)/disorder(s) especially for the treatment or preventionof organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant,or the management of immune-mediated diseases (autoimmune diseases).
